In summary, our findings suggest that plasma DNA can be detected and potentially used to non-invasively stratify fibrosis risk in NAFLD according to methylation levels at DMRs within the PPARγ gene promoter. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.